Pharmafile Logo

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains…

- PMLiVE

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.

Specific challenges facing the oncology field

1. Increased competition and evolving standard of care

New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.

With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.

Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…

Read the full article here.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Alternative Approaches to Personalized Medicine in Oncology

Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how...

Reimagining Healthcare Using Mobile Health Technologies

Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into...

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

CRM Design and Optimization for Life Science Organizations

John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical...

Enabling Patient-Focused Research Through Virtual Clinical Trials

Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we will discuss data privacy concerns, the role of digital...

Innovative Approaches to Managing Mental Health Conditions

Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and...

Looking back at the year when everything changed

COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families.

PRESS RELEASE: IMPETUS DIGITAL LAUNCHES INSITE EVENTâ„¢

Impetus Digital launches InSite Event™ -  the most comprehensive virtual event platform for life science companies, delivered with white glove service

Risk Management, Ethics, and Compliance Considerations in the New Normal

Myriam Prescott, Head of Ethics, Risks and Compliance - Oncology, Novartis Canada, dissects the importance of effective patient engagement and strong compliance & monitoring programs. We also dive into the...

A Deep-Dive into the COVID-19 Pandemic and its Secondary Effects

Dr. Farah Fourcand, Author of Pandemic Manifesto, shares her experience working on the frontlines of the COVID-19 pandemic. She also dives into the psychological impact of COVID-19, lessons learned from the...